Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Surg Oncol ; 47(9): 2405-2413, 2021 09.
Article in English | MEDLINE | ID: mdl-34030920

ABSTRACT

INTRODUCTION: With evolving treatment strategies aiming at prevention or early detection of metachronous peritoneal metastases (PM), identification of high-risk colon cancer patients becomes increasingly important. This study aimed to evaluate differences between pT4a (peritoneal penetration) and pT4b (invasion of other organs/structures) subcategories regarding risk of PM and other oncological outcomes. MATERIALS AND METHODS: From eight databases deriving from four countries, patients who underwent curative intent treatment for pT4N0-2M0 primary colon cancer were included. Primary outcome was the 5-year metachronous PM rate assessed by Kaplan-Meier analysis. Independent predictors for metachronous PM were identified by Cox regression analysis. Secondary endpoints included 5-year local and distant recurrence rates, and 5-year disease free and overall survival (DFS, OS). RESULTS: In total, 665 patients with pT4a and 187 patients with pT4b colon cancer were included. Median follow-up was 38 months (IQR 23-60). Five-year PM rate was 24.7% and 12.2% for pT4a and pT4b categories, respectively (p = 0.005). Independent predictors for metachronous PM were female sex, right-sided colon cancer, peritumoral abscess, pT4a, pN2, R1 resection, signet ring cell histology and postoperative surgical site infections. Five-year local recurrence rate was 14% in both pT4a and pT4b cancer (p = 0.138). Corresponding five-year distant metastases rates were 35% and 28% (p = 0.138). Five-year DFS and OS were 54% vs. 62% (p = 0.095) and 63% vs. 68% (p = 0.148) for pT4a vs. pT4b categories, respectively. CONCLUSION: Patients with pT4a colon cancer have a higher risk of metachronous PM than pT4b patients. This observation has important implications for early detection and future adjuvant treatment strategies.


Subject(s)
Adenocarcinoma/secondary , Carcinoma, Signet Ring Cell/secondary , Colonic Neoplasms/pathology , Neoplasm Recurrence, Local/epidemiology , Peritoneal Neoplasms/secondary , Abdominal Abscess/epidemiology , Adenocarcinoma/therapy , Aged , Carcinoma, Signet Ring Cell/therapy , Chemotherapy, Adjuvant , Cohort Studies , Colon, Ascending/pathology , Colon, Transverse/pathology , Colonic Neoplasms/therapy , Disease-Free Survival , Female , Humans , Internationality , Male , Middle Aged , Neoadjuvant Therapy , Neoplasm Invasiveness , Neoplasm Staging , Peritoneal Neoplasms/epidemiology , Risk Factors , Sex Factors , Surgical Wound Infection/epidemiology , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...